KRIBB11 induces apoptosis and cell cycle arrest in NSCLC, especially in combination therapies, by inhibiting the PI3K/AKT pathway, increasing ROS, and activating DNA damage responses (Zhang et al., 2024). Here, AKT1 is linked to non-small cell lung carcinoma.